Compare PHAT & PGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHAT | PGY |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | 518 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 894.0M | 928.4M |
| IPO Year | 2019 | N/A |
| Metric | PHAT | PGY |
|---|---|---|
| Price | $10.67 | $11.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $19.50 | ★ $34.50 |
| AVG Volume (30 Days) | 940.4K | ★ 2.6M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $175,110,000.00 | N/A |
| Revenue This Year | $92.15 | $14.27 |
| Revenue Next Year | $59.79 | $14.19 |
| P/E Ratio | ★ N/A | $13.54 |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $2.21 | $8.50 |
| 52 Week High | $18.31 | $44.99 |
| Indicator | PHAT | PGY |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 41.74 |
| Support Level | $10.06 | $10.46 |
| Resistance Level | $12.62 | $25.47 |
| Average True Range (ATR) | 0.67 | 0.57 |
| MACD | 0.08 | 0.32 |
| Stochastic Oscillator | 35.00 | 47.01 |
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.